Navigation Links
ATS Medical Expects First Quarter Revenue of $14.6 to $14.8 Million
Date:4/3/2008

Revenue from non-mechanical heart valve businesses expected to grow by over

100%, year-over-year

MINNEAPOLIS, April 3, 2008 /PRNewswire-FirstCall/ -- ATS Medical, Inc. (Nasdaq: ATSI), manufacturer and marketer of state-of-the-art cardiac surgery products and services, today reported preliminary revenue results for the first quarter of 2008.

(Logo: http://www.newscom.com/cgi-bin/prnh/20040202/ATSILOGO)

The Company currently expects revenue for the first quarter 2008 to be between $14.6 and $14.8 million, which would represent an increase of approximately 36% over first quarter 2007 revenue of $10.8 million. Revenues from products and services other than the Company's mechanical heart valves are expected to exceed $5.0 million, a quarterly record, and represent approximately 34% of total revenue during the first quarter of 2008 compared with 23% in the first quarter of 2007 and 33% in the fourth quarter of 2007. The Company expects to release its first quarter results on May 5, 2008.

"The first quarter was a strong start to 2008, with higher revenue across all our business segments," said Michael Dale, Chairman, President and CEO of ATS Medical. "ATS CryoMaze(TM) surgical ablation revenue was especially strong, up approximately 160% over the prior year's first quarter. We were also pleased with the continued increase in revenue from mechanical heart valves internationally, up approximately 32% from last year."

"While we continue to seek FDA approval of our ATS 3f(R) Aortic Bioprosthesis tissue valve, we have maintained our focus on growing revenue in each of our other businesses, and witnessed sequential growth in every business segment, both domestically and internationally. We were also able to sequentially grow U.S. mechanical heart valve sales by over 10%, the second consecutive quarter of growth, due in part to a positive reception of our new ATS Open Pivot(R) AP360(TM) mechanical valve. We believe our diverse and highly differentiated product portfolio will be the key catalyst to continuing our growth throughout 2008, and are pleased that this quarter's results reflect our execution across all segments," concluded Mr. Dale.

About ATS Medical

ATS Medical, Inc. provides innovative products and services focused on cardiac surgery. The Company, global in scope, is headquartered in Minneapolis, Minnesota. More than 145,000 ATS Open Pivot(R) Heart Valves, which utilize a unique pivot design resulting in exceptional performance and low risk profile, have been implanted in patients worldwide. The ATS 3f(R) brand encompasses multiple tissue heart valve product offerings at varying steps from market introductions to clinical trials to development projects that incorporate less invasive valve replacement technology. ATS Medical's focus on serving the cardiac surgery community is further strengthened by offerings that include ATS Simulus(R) annuloplasty products for heart valve repair and ATS CryoMaze(TM) surgical ablation products. The ATS Medical web site is http://www.atsmedical.com.

Safe Harbor

This Press Release contains forward-looking statements that may include statements regarding intent, belief or current expectations of the Company and its management. Actual results could differ materially from those projected in the forward looking statements as a result of a number of important factors, including the results of clinical trials, the timing of regulatory approvals, the integration of 3f Therapeutics and the surgical cryoablation business of CryoCath Technologies, Inc., regulatory actions, competition, pricing pressures, supplier actions and management of growth. For a discussion of these and other risks and uncertainties that could affect the Company's activities and results, please refer to the Company's filings with the Securities and Exchange Commission, including its Form 10-K for the year ended December 31, 2007.


'/>"/>
SOURCE ATS Medical, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. DaVita Announces Retirement of Former Chief Medical Officer Charles J. McAllister, M.D.
2. Tryton Medical, Inc. Closes $14 Million Financing
3. Bayer HealthCare Affiliate MEDRAD Successfully Completes Tender Offer for Shares of Possis Medical; Announces Subsequent Offering Period
4. Boston Biomedical Research Institute Maintains Baa3 Rating from Moodys
5. Varian Medical Systems Schedules Second Quarter FY2008 News Release and Conference Call
6. Galil Medical Announces the Appointment of Martin J. Emerson as President and Chief Executive Officer
7. BioMS Medical to present at BioCentury Conference
8. SBT Acquisition Inc. Successfully Completes Tender Offer for Shares of Lifecore Biomedical, Inc.
9. Medical Research Award Goes to Adult Stem Cell Scientists at a Kansas Not-for-Profit Organization
10. Inverness Medical Innovations to Close Cholestech, HemoSense and BioStar Facilities
11. Inverness Medical Innovations to Participate at Bank of America 2008 Smid Cap Conference on March 26, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... DUBLIN , Feb. 16, 2017 ... the "Synthetic Biology: Global Markets" report to ... ... synthetic-biology products (synthetic genes, biobrick parts, delivery plasmids, chassis ... DNA synthesis and assembly, genome editing, bioinformatics and specialty ...
(Date:2/16/2017)... PALM BEACH, Florida , February 16, 2017 ... vastly improving with the infusion of innovative telemedicine ... patient monitoring services that are experiencing a boom ... evolve with the advancement of technologies, services and ... Technologies Inc. (OTC: RQHTF) (TSX-V: RHT), Cellectar Biosciences, ...
(Date:2/16/2017)... N.J. , Feb. 16, 2017  Champions Oncology, ... in the development and sale of advanced technology solutions ... oncology drugs, today announced the addition of new cohorts ... These new models will expand Champions, product line ... head and neck cancer, AML, and non-small cell lung ...
(Date:2/16/2017)... Feb. 16, 2017  Rhythm, a biopharmaceutical ... deficiencies that result in life-threatening metabolic disorders, ... million mezzanine round of financing with existing ... Capital, New Enterprise Associates, Pfizer Venture Investments, ... healthcare investment fund. Rhythm will use the ...
Breaking Biology Technology:
(Date:2/13/2017)... Feb. 13, 2017  RSA Conference -- RSA, a ... is designed to enhance fraud detection and investigation ... the RSA Fraud & Risk Intelligence Suite. The ... leverage additional insights from internal and external sources ... protect their customers from targeted cybercrime attacks. ...
(Date:2/8/2017)... Feb. 7, 2017  Aware, Inc. (NASDAQ: AWRE ... reported financial results for its quarter and year ended December ... of 2016 was $3.9 million compared to $6.9 million in ... quarter of 2016 was $0.6 million compared to $2.6 million ... fourth quarter of 2016 was $0.5 million, or $0.02 per ...
(Date:2/7/2017)... Feb. 7, 2017 Zimmer Biomet Holdings, Inc. ... healthcare, will present at the LEERINK Partners 6th Annual ... Hotel on Wednesday, February 15, 2017 at 10 a.m. ... the presentation can be accessed at http://wsw.com/webcast/leerink28/zbh .  ... conference via Zimmer Biomet,s Investor Relations website at ...
Breaking Biology News(10 mins):